• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Peripheral artery disease Market

    ID: MRFR/MED/1011-CR
    137 Pages
    Kinjoll Dey
    February 2020

    Peripheral Artery Disease Market Research Report Information By Treatment Type (Device, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Others), By Drugs (Lipid Lowering Drugs, Triple-H Therapy, Glucose Regulating Drugs, Blood Clot Preventing Drugs, Inotropes, Thrombolytic Agents, and Anti-Inflammatory Agents), By End User (Hospitals & Clinics, and Ambulatory Surgical Clinics) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Peripheral artery disease Market Infographic
    Purchase Options

    Peripheral artery disease Market Summary

    As per MRFR analysis, the Peripheral Artery Disease Market Size was estimated at 2.899 USD Billion in 2024. The Peripheral Artery Disease industry is projected to grow from 3.096 USD Billion in 2025 to 5.979 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.8 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    <p>The Peripheral Artery Disease Market is poised for substantial growth driven by technological advancements and demographic shifts.</p>

    • Minimally invasive procedures are gaining traction, enhancing patient outcomes and recovery times.
    • Digital health integration is transforming patient management and monitoring in the treatment of Peripheral Artery Disease.
    • The aging population in North America is contributing to a rising prevalence of Peripheral Artery Disease, necessitating innovative treatment solutions.
    • Rising healthcare expenditure and advancements in medical technology are key drivers propelling the market forward, particularly in the device and lipid-lowering drug segments.

    Market Size & Forecast

    2024 Market Size 2.899 (USD Billion)
    2035 Market Size 5.979 (USD Billion)
    CAGR (2025 - 2035) 6.8%

    Major Players

    Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), Bayer AG (DE), Philips (NL), Terumo Corporation (JP), Cardinal Health (US), Cook Medical (US), Stryker Corporation (US)

    Peripheral artery disease Market Trends

    The Peripheral Artery Disease Market is currently experiencing notable transformations driven by advancements in medical technology and an increasing awareness of cardiovascular health. As healthcare providers and patients alike recognize the importance of early diagnosis and intervention, the demand for innovative treatment options is on the rise. This market is characterized by a growing emphasis on minimally invasive procedures, which are perceived to offer enhanced recovery times and reduced complications compared to traditional surgical methods. Furthermore, the integration of digital health solutions, such as telemedicine and mobile health applications, is reshaping patient management and follow-up care, thereby improving overall outcomes for individuals suffering from this condition. In addition to technological advancements, demographic shifts are influencing the Peripheral Artery Disease Market. An aging population, coupled with rising rates of diabetes and obesity, is likely to contribute to an increased prevalence of peripheral artery disease. This trend suggests a need for more comprehensive treatment strategies and preventive measures. As healthcare systems adapt to these changes, collaboration among stakeholders, including pharmaceutical companies, medical device manufacturers, and healthcare providers, appears essential for fostering innovation and improving patient care. Overall, the Peripheral Artery Disease Market is poised for growth, driven by a combination of technological progress and evolving patient needs.

    Minimally Invasive Procedures

    The trend towards minimally invasive techniques is gaining traction within the Peripheral Artery Disease Market. These procedures are often associated with shorter recovery times and lower risks of complications, making them increasingly appealing to both patients and healthcare providers.

    Digital Health Integration

    The incorporation of digital health technologies is reshaping the landscape of the Peripheral Artery Disease Market. Telemedicine and mobile health applications are enhancing patient engagement and facilitating remote monitoring, which may lead to improved management of the disease.

    Aging Population and Lifestyle Factors

    The demographic shift towards an older population, combined with lifestyle-related health issues, is likely to drive the demand for Peripheral Artery Disease treatments. This trend underscores the necessity for targeted interventions and preventive strategies to address the growing prevalence of the condition.

    The increasing prevalence of risk factors such as diabetes and hypertension is likely to drive the demand for innovative treatment options in the Peripheral Artery Disease market.

    Centers for Disease Control and Prevention (CDC)

    Peripheral artery disease Market Drivers

    Increased Healthcare Expenditure

    Rising healthcare expenditure across various regions is a crucial factor driving the Peripheral Artery Disease Market. Governments and private sectors are investing more in healthcare infrastructure, which includes the development of specialized facilities for vascular diseases. This trend is evident in many countries, where healthcare budgets are being allocated to improve access to diagnostic and therapeutic services for PAD. For example, the World Health Organization has reported that healthcare spending is expected to rise significantly in the coming years, which may lead to enhanced availability of PAD treatments. Consequently, this increased financial commitment is likely to support the growth of the Peripheral Artery Disease Market, as more patients gain access to necessary care.

    Advancements in Medical Technology

    Technological innovations in the field of vascular interventions are significantly influencing the Peripheral Artery Disease Market. The development of minimally invasive techniques, such as angioplasty and stenting, has revolutionized treatment approaches, offering patients safer and more effective options. For instance, the introduction of drug-eluting stents has shown promising results in reducing restenosis rates. Additionally, advancements in imaging technologies, such as ultrasound and MRI, enhance diagnostic accuracy, facilitating timely interventions. These technological strides not only improve patient outcomes but also attract investment in research and development, thereby fostering growth within the Peripheral Artery Disease Market. As healthcare providers increasingly adopt these advanced technologies, the market is poised for substantial expansion.

    Emerging Markets and Economic Growth

    Emerging markets are becoming increasingly important in the Peripheral Artery Disease Market due to their economic growth and rising healthcare needs. As countries develop, there is a corresponding increase in lifestyle-related diseases, including PAD. This trend is particularly evident in regions experiencing rapid urbanization and changes in dietary habits. For instance, countries in Asia and Latin America are witnessing a surge in cardiovascular diseases, prompting governments to enhance healthcare services. The expansion of healthcare infrastructure in these regions is likely to facilitate access to PAD treatments, thereby driving market growth. As these emerging markets continue to evolve, they present significant opportunities for stakeholders in the Peripheral Artery Disease Market.

    Growing Awareness and Education Initiatives

    The rise in awareness and education initiatives regarding Peripheral Artery Disease is contributing to the expansion of the Peripheral Artery Disease Market. Healthcare organizations and advocacy groups are actively promoting knowledge about PAD, its risk factors, and the importance of early detection. This heightened awareness is likely to lead to increased screening and diagnosis rates, which can result in a larger patient population seeking treatment. Furthermore, educational campaigns targeting healthcare professionals are essential for improving clinical practices and ensuring timely interventions. As more individuals become informed about PAD, the demand for effective treatment options is expected to grow, thereby driving the Peripheral Artery Disease Market.

    Rising Prevalence of Peripheral Artery Disease

    The increasing incidence of Peripheral Artery Disease (PAD) is a primary driver for the Peripheral Artery Disease Market. As the population ages, the prevalence of risk factors such as diabetes, hypertension, and obesity rises, leading to a higher number of PAD cases. According to recent estimates, approximately 8 to 12 million individuals in the United States alone are affected by PAD, which underscores the urgent need for effective treatment options. This growing patient population is likely to stimulate demand for innovative therapies and medical devices, thereby propelling the Peripheral Artery Disease Market forward. Furthermore, awareness campaigns aimed at educating the public about PAD symptoms and risks may contribute to earlier diagnosis and treatment, further expanding the market.

    Market Segment Insights

    By By Type: Device (Largest) vs. Catheters (Fastest-Growing)

    The Peripheral Artery Disease Market is notably characterized by a diverse range of products, primarily segmented into Devices, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Others. Among these, Devices hold a significant market share, attributed to their prevalence in treatment protocols. Catheters, on the other hand, are gaining rapid traction due to technological advancements and the increasing preference for minimally invasive procedures, reflecting a notable shift in consumer demand toward innovative treatment options.

    Devices: Device (Dominant) vs. Catheters (Emerging)

    Devices serve as the cornerstone of the Peripheral Artery Disease treatment landscape, demonstrating robust performance owing to their established role in procedural interventions. They encompass a variety of forms, including balloons and stents, which facilitate improved blood flow and patient outcomes. In contrast, Catheters have emerged as a vital segment, driven by their minimally invasive nature and ease of use. As the healthcare ecosystem shifts towards procedures that require less recovery time, Catheters are positioned to capture an increasing share of the market, appealing to both patients and healthcare providers who prioritize efficiency and efficacy.

    By By Drugs: Lipid-Lowering Drugs (Largest) vs. Blood Clot Preventing Drugs (Fastest-Growing)

    The drugs segment in the Peripheral Artery Disease market exhibits a diverse distribution characterized by several key players. Lipid-Lowering Drugs hold the largest share, attributed to their essential role in managing cholesterol levels, thus reducing cardiovascular risks associated with the disease. In contrast, Blood Clot Preventing Drugs are emerging as the fastest-growing category. Their uptake reflects a shift towards preventative therapies amid rising awareness of thrombotic complications in patients with Peripheral Artery Disease. Several growth trends are impacting this segment. The increasing prevalence of Peripheral Artery Disease and the aging population are driving demand for effective pharmaceutical interventions. Innovation in drug formulations, including advances in combination therapies such as Triple-H Therapy and improved efficacy of Glucose Regulating Drugs, are contributing to market expansion. As healthcare providers emphasize preventative care, the use of Blood Clot Preventing Drugs is likely to see significant growth in the coming years.

    Lipid-Lowering Drugs (Dominant) vs. Glucose Regulating Drugs (Emerging)

    Lipid-Lowering Drugs remain the dominant force in the Peripheral Artery Disease market, primarily due to their established role in managing associated cardiovascular risks. Their effectiveness in lowering LDL cholesterol levels significantly contributes to reducing the incidence of heart attacks and strokes in patients suffering from the condition. On the other hand, Glucose Regulating Drugs are recognized as an emerging category, particularly in the context of diabetic patients with Peripheral Artery Disease. With the growing relationship between glucose control, vascular health, and cardiovascular outcomes, these drugs are gaining attention. Their ability to mitigate complications associated with diabetes presents a vital marketing opportunity, especially as the healthcare landscape moves towards a more integrated approach to chronic disease management.

    By By End User: Hospitals & Clinics (Largest) vs. Ambulatory Surgical Clinics (Fastest-Growing)

    In the Peripheral Artery Disease (PAD) market, Hospitals & Clinics dominate the end-user segment due to their established infrastructure and comprehensive treatment capabilities. They are equipped with specialized medical personnel and advanced technologies, leading to a significant preference among patients for receiving specialized care in these settings. Consequently, this segment holds the largest market share, making it pivotal for stakeholders looking to understand the dynamics of PAD treatment. On the other hand, Ambulatory Surgical Clinics are emerging as the fastest-growing segment in the PAD market. Their rapid growth can be attributed to a rising demand for outpatient care, which allows for less invasive procedures, quicker recovery times, and overall cost-effectiveness. As patients increasingly favor minimally invasive options that reduce hospital stay, this segment is poised for substantial expansion in the coming years.

    Hospitals & Clinics (Dominant) vs. Ambulatory Surgical Clinics (Emerging)

    Hospitals & Clinics serve as the dominant players in the Peripheral Artery Disease market, primarily due to their extensive resources, including specialized teams trained in managing PAD. These institutions offer a spectrum of treatments from diagnostic testing to complex surgical interventions, providing a holistic approach to patient care. In contrast, Ambulatory Surgical Clinics, recognized as the emerging segment, specialize in outpatient procedures that cater to the growing trend of minimally invasive treatments for PAD. These clinics promote efficiency, often supported by technological advancements that facilitate operations within a compact structure. This shift towards outpatient services aligns with patient preferences for convenience and cost savings, establishing Ambulatory Surgical Clinics as a vital component of the evolving healthcare landscape.

    Get more detailed insights about Peripheral artery disease Market

    Regional Insights

    By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Peripheral Artery Disease market area will dominate this market, owing to an increase in the instances of cardiovascular diseases. In addition, the solid presence of industry players will boost market growth in this region.

    Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2 PERIPHERAL ARTERY DISEASE MARKET SHARE BY REGION 2023 (USD Billion)PERIPHERAL ARTERY DISEASE MARKET SHARE BY REGION 2022

    Source Secondary Research, Primary Research, MRFR Database and Analyst Review

    Europe Peripheral Artery Disease market accounts for the second-largest market share due to the rising smoking, and obesity among the population within the region. Further, the German Peripheral Artery Disease market held the largest market share, and the UK Peripheral Artery Disease market was the fastest growing market in the European region

    The Asia-Pacific Peripheral Artery Disease Market is expected to grow at the quickest CAGR from the period of 2023 to 2032. This is due to growing healthcare expenditures and growing geriatric population. Moreover, China’s Peripheral Artery Disease market held the largest market share, and the Indian Peripheral Artery Disease market was the fastest growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    Leading market players are undergoing various innovations activity to diversify their product & service offerings, which will help the Peripheral Artery Disease market, grow even more. Market participants are undertaking various strategic tactics to grow their presence, with key market developments including new product innovations, contracts & agreements, mergers & acquisitions, higher investments, partnerships, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Peripheral Artery Disease industry must offer cost-effective items.

    The producers are utilizing locally available raw materials to stand in the competition in the Peripheral Artery Disease industry to benefit clients and increase the market sector. In recent years, the Peripheral Artery Disease industry has offered some of the most significant advantages to medicine. Major players in the Peripheral Artery Disease market, including Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation, Biotronik Cardinal Health., and others, are attempting to increase market demand by investing in research and development operations.

    Becton Dickinson and Co. (BD) is a manufacturer and distributor of medical equipment, reagents, and instruments is. Syringes and pen needles, intravenous catheters, infusion pumps, disposables, automated medication dispensing and supply management systems, pre-fillable drug delivery systems, respiratory ventilation and diagnostic equipment and consumables, items for the secure collection and transportation of diagnostic specimens, instruments and reagent systems to detect a variety of infectious diseases and cancers, and clinical research tools are among its main products.

    Researchers who are working in the branch of life sciences, hospitals, clinics, the pharmaceutical sector, and the general public can all benefit from BD's products. In August 2022, The first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB) has begun, according to BD (Becton, Dickinson and business) (NYSE BDX), a top  medical technology business.

    Koninklijke Philips NV (Philips) is a diversified technology firm that creates and produces consumer electronics and medical solutions. Diagnostic imaging, enterprise diagnostic informatics, image-guided therapy, ultrasound, monitoring and analytics, sleep and respiratory care, population health management, linked care informatics, and therapeutic care are all sectors in which the business provides products and solutions. Products available include power toothbrushes, brush heads, baby bottles, sterilisers, breast pumps, shavers, groomers, trimmers, and items for skin, hair, and hair removal. It also sells personal care and dental healthcare items.

    In August 2020, A deal to acquire Intact Vascular, Inc., a company based in the United States that creates medical equipment for minimally invasive peripheral vascular operations, was announced by Royal Philips.

    Key Companies in the Peripheral artery disease Market market include

    Industry Developments

    • Q2 2024: LimFlow Announces FDA Approval of LimFlow System for Treatment of Chronic Limb-Threatening Ischemia (CLTI) LimFlow received FDA premarket approval for its LimFlow System, a minimally invasive device designed to treat patients with chronic limb-threatening ischemia, a severe form of peripheral artery disease.
    • Q2 2024: CardioFlow Receives CE Mark Approval for Peripheral Artery Disease Device CardioFlow announced it has received CE Mark approval for its new peripheral artery disease treatment device, enabling commercialization in the European Union.
    • Q2 2024: PQ Bypass Announces First Commercial Use of DETOUR System Following FDA Approval PQ Bypass reported the first commercial use of its DETOUR System for treating long femoropopliteal lesions in peripheral artery disease patients, following recent FDA approval.
    • Q3 2024: Shockwave Medical Announces FDA Clearance of Shockwave M5+ Peripheral IVL Catheter Shockwave Medical received FDA clearance for its M5+ Peripheral Intravascular Lithotripsy (IVL) Catheter, expanding its portfolio for treating peripheral artery disease.
    • Q3 2024: Boston Scientific Completes Acquisition of Silk Road Medical Boston Scientific completed its acquisition of Silk Road Medical, a company specializing in devices for the treatment of vascular diseases including peripheral artery disease.
    • Q3 2024: Inari Medical Announces FDA Clearance for ClotTriever BOLD Catheter for Peripheral Thrombectomy Inari Medical received FDA clearance for its ClotTriever BOLD catheter, designed for the removal of blood clots in patients with peripheral artery disease.
    • Q4 2024: BD Launches New Peripheral Artery Disease Balloon Catheter in the U.S. BD (Becton, Dickinson and Company) launched a new balloon catheter for the treatment of peripheral artery disease in the United States.
    • Q4 2024: Medtronic Announces FDA Approval of IN.PACT AV Drug-Coated Balloon for Peripheral Artery Disease Medtronic received FDA approval for its IN.PACT AV drug-coated balloon, expanding its portfolio of devices for the treatment of peripheral artery disease.
    • Q1 2025: Penumbra Announces European Launch of Indigo Aspiration System for Peripheral Artery Disease Penumbra launched its Indigo Aspiration System in Europe, designed for the removal of thrombus in patients with peripheral artery disease.
    • Q1 2025: Abbott Receives FDA Approval for New Peripheral Stent System Abbott received FDA approval for its new peripheral stent system, intended to treat patients with peripheral artery disease.
    • Q2 2025: Philips Launches New Image-Guided Therapy System for Peripheral Artery Disease Philips launched a new image-guided therapy system designed to improve the diagnosis and treatment of peripheral artery disease.
    • Q2 2025: Surmodics Announces FDA Approval of SurVeil Drug-Coated Balloon for Peripheral Artery Disease Surmodics received FDA approval for its SurVeil drug-coated balloon, a device for the treatment of peripheral artery disease.

    Future Outlook

    Peripheral artery disease Market Future Outlook

    The Global Peripheral Artery Disease Market is projected to grow at a 6.80% CAGR from 2024 to 2032, driven by increasing prevalence, technological advancements, and rising awareness.

    New opportunities lie in:

    • Develop innovative minimally invasive treatment options to enhance patient outcomes. Leverage telehealth solutions for remote monitoring and management of PAD patients. Invest in targeted marketing campaigns to raise awareness and drive early diagnosis.

    By 2035, the market is expected to demonstrate robust growth, reflecting advancements in treatment and increased patient engagement.

    Market Segmentation

    Peripheral Artery Disease Drugs Outlook

    • Lipid Lowering Drugs
    • Triple-H Therapy
    • Glucose Regulating Drugs
    • Blood Clot Preventing Drugs
    • Inotropes
    • Thrombolytic Agents
    • Anti-Inflammatory Agents

    Peripheral Artery Disease End User Outlook

    • Hospitals & Clinics
    • Ambulatory Surgical Clinics

    Peripheral Artery Disease Regional Outlook

    • {"North America"=>["US"
    • "Canada"]}
    • {"Europe"=>["Germany"
    • "France"
    • "UK"
    • "Italy"
    • "Spain"
    • "Rest of Europe"]}
    • {"Asia-Pacific"=>["China"
    • "Japan"
    • "India"
    • "Australia"
    • "South Korea"
    • "Rest of Asia-Pacific"]}
    • {"Rest of the World"=>["Middle East"
    • "Africa"
    • "Latin America"]}

    Peripheral Artery Disease Treatment Type Outlook

    • Device
    • Catheters
    • Plaque Modification Devices
    • Hemodynamic Flow Alteration Devices
    • Others

    Report Scope

     

    Attribute/MetricDetails
    Market Size 2024USD 2.90 Billion
    Market Size 20355.98 (Value (USD Billion))
    Compound Annual Growth Rate (CAGR)6.80% (2025 - 2035)
    Base Year2024
    Market Forecast Period2025 - 2035
    Historical Data2018-2022
    Market Forecast UnitsValue (USD Billion)
    Report CoverageRevenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments CoveredTreatment Type, Drugs, End User, and Region
    Geographies CoveredNorth America, Europe, Asia Pacific, and the Rest of the World
    Countries CoveredThe US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies ProfiledPhilips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation
    Key Market OpportunitiesGrowing obesity and elderly population
    Key Market DynamicsIncrease in healthcare expenditures and rising consumer spending over health and fitness
    Market Size 20253.10 (Value (USD Billion))

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    What is the projected growth of the Peripheral Artery Disease market?

    The Peripheral Artery Disease market is the expected increase in total market value of 5.98 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

    What is the size of the Peripheral Artery Disease market?

    Peripheral Artery Disease market size was valued at approximately 2.9 billion USD in 2024. This figure will reach 5.98 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

    What is the CAGR of the Peripheral Artery Disease market?

    Peripheral Artery Disease market is expected to grow at a CAGR of 6.8% between 2025 and 2035.

    How much will the Peripheral Artery Disease market be worth by 2035?

    Peripheral Artery Disease market is expected to be worth of 5.98 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

    How will the Peripheral Artery Disease market perform over the next 10 years?

    Over the next 10 years the Peripheral Artery Disease market is expected to shift from usd billion 2.9 to 5.98 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

    Which region held the largest market share in the Peripheral Artery Disease market?

    North America had the largest share in the market

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions